Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 4834 results
Cynapsus Therapeutics commences Phase II clinical trials in US
Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson's disease, has announced that following communication from the United States Food and Drug Administration, Phase II clinical studies for APL-130277 will commence immediately.
Drug Research > Drug Discovery & Development > News
MYOS enters into R&D agreement with Cloud Pharmaceuticals
MYOS, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into a research and development agreement with Cloud Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Isis Pharmaceuticals initiates Phase 2 study of ISIS-APO(a) in patients with high Lp(a)
Isis Pharmaceuticals announced the initiation of a Phase 2 study evaluating ISIS-APO(a) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
Drug Research > Drug Discovery & Development > News
Lilly, Immunocore to jointly discover and develop new cancer therapies
By PBR Staff Writer
US-based Eli Lilly and Company has entered into a co-discovery and co-development collaboration with British biotechnology firm Immunocore to research and potentially develop new T cell-based cancer therapies.
Drug Research > Drug Discovery & Development > News
BioLineRx reports results from Phase 1/2 study for celiac treatment
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today unblinded results from its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease.
Drug Research > Drug Discovery & Development > News
ChromaDex begins first human clinical study to confirm ChromaDex's NIAGEN Nicotinamide Riboside will increase NAD+
ChromaDex, an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN, the first and only commercially available form of nicotinamide riboside (NR).
Drug Research > Drug Discovery & Development > News
Roche's Phase III trial of melanoma combination therapy meets primary endpoint
By PBR Staff Writer
Roche has released positive results from the Phase III coBRIM trial of an investigational MEK inhibitor cobimetinib, used in combination with its BRAF inhibitor Zelboraf, to treat patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
Drug Research > Drug Discovery & Development > News
Helix BioPharma announces completion of private placement
BioPharma, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, has announced it has completed a private placement with net proceeds in excess of CAD5.4 million, after fees and expenses associated with the placement.
Drug Research > Drug Discovery & Development > News
Ipsen, Galderma become exclusive partners for development and marketing of neurotoxins
Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on dermatology and skin health, has announced that they have significantly expanded the scope of their neurotoxin partnership.
Drug Research > Drug Discovery & Development > News
HD Biosciences, Marshall University enter drug discovery co-development deal
By PBR Staff Writer
HD Biosciences, a China-based biology-focused preclinical drug discovery contract research organization (CRO), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine have announced a new partnership to co-develop potential anti-cancer drugs for unmet healthcare needs in both international and Chinese markets.
Drug Research > Drug Discovery & Development > News
Threshold starts dosing in Phase I/II trial of myeloma combination drug TH-302/Bortezomib
By PBR Staff Writer
Threshold Pharmaceuticals has initiated dosing patients in the final stage of an ongoing Phase I/II trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade) and low-dose dexamethasone (TBorD) for the treatment of relapsed/refractory multiple myeloma.
Drug Research > Drug Discovery & Development > News
Compugen discloses achievement of milestone in cancer immunotherapy collaboration with Bayer
Compugen has disclosed that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (Bayer).
Drug Research > Drug Discovery & Development > News
BioMarin gets Health Canada approval of VIMIZIM to treat morquio a syndrome
BioMarin Pharmaceutical has announced that Health Canada has approved VIMIZIM(elosulfase alfa) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (MPS IVA), also known as Morquio A syndrome.
Drug Research > Drug Discovery & Development > News
Yabao Pharma, Eli Lilly to jointly develop diabetes treatment
By PBR Staff Writer
China-based Yabao Pharmaceutical has entered into a strategic partnership with Eli Lilly and Company to jointly develop Lilly's glucokinase activator (GKA), LY2608204, which has completed Phase I studies in the US in addition to extensive pre-clinical development.
Drug Research > Drug Discovery & Development > News
Bayer's Nexavar gets Health Canada approval for differentiated thyroid cancer
Bayer is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced or metastatic, progressive, differentiated thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

IDT - Biopharmaceutical Development & Contract Manufacturing Services
IDT Biologika GmbH is an innovative, privately-held company with more than 90 years of experience in researching, developing, manufacturing and marketing of biologics. IDT operates one of Europe’s premiere integrated biological and pharmaceutical development and manufacturing facilities.... Drug Research > Drug Discovery & Development > Suppliers
PolyPeptide Group - Proprietary and Generic GMP-Grade Peptides
The PolyPeptide Group is a privately-held group of manufacturing companies that focuses on proprietary and generic GMP-grade peptides for the pharmaceutical, cosmetic and biotechnological market.... Drug Research > Drug Discovery & Development > Suppliers
Lohmann Therapy System (LTS) - Transdermal Therapeutic Systems and Oral Thin Films
LTS is the market leader in alternative drug delivery systems, in the form of transdermal therapeutic systems and oral thin films. We develop and manufacture drug delivery systems that offer patients reliable therapeutic efficacy with total comfort and convenience.... Drug Research > Drug Discovery & Development > Suppliers
Glycotope - Contract Manufacturer of Recombinant Proteins
Glycotope Biotechnology offers GMP-compliant biotechnological contract manufacturing, based on animal cell culture systems in fed-batch or perfusion fermentation technologies. We are compliant with all criteria within the European Pharmaceutical legislation, the European Pharmacopoeia, as well as EU and ICH guidelines.... Drug Research > Drug Discovery & Development > Suppliers
The Electrospinning Company - Polymer Scaffolds for 3D Cell Culture
The Electrospinning Company develops and manufactures electrospun polymer scaffolds which are incorporated into standard tissue culture plates. These provide an ideal environment for supporting the growth of cells in 3D.... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

Freeze Drying - Large-Scale Production for Biologics By IDT Biologika
IDT's new world-class multi-purpose high-speed filling and large-scale freeze-drying plant for human vaccines (liquid and lyophilized) is equipped to handle and respond to the complex quality and safety demands of current and future live vaccines and immunotherapeutic medicines.... Drug Research > Drug Discovery & Development > White Papers IDT Biopharmaceutical Contract Manufacturing By IDT Biologika
IDT's special expertise and capabilities include: development and aseptic filling services for parenterals in syringes, vials and ampoules; proven expertise in processing of biopharmaceutical and chemical substances; leading competence in freeze drying of narcotics; and integrated bio and pharma manufacturing site with comprehensive quality control services.... Drug Research > Drug Discovery & Development > White Papers IDT Human Vaccines Contract Manufacturing By IDT Biologika
IDT produces a wide variety of vaccines for clinical testing and is also developing new technologies for many innovative and future orientated human vaccines, for instance against tuberculosis, AIDS and malaria. Over 20 different vaccines for clinical trials in humans have been handled by IDT to date.... Drug Research > Drug Discovery & Development > White Papers Vaccines - Creating Value, Protecting Lives By IDT Biologika
IDT is a knowledgeable partner and an expert in the field of biologics contract manufacturing. IDT is focused on four business segments: animal health, vaccines, pharmaceuticals and quality control. We are a vital link in the development chain of new vaccines. Our core competency is in the contract production of viral and bacterial vaccines. We offer a comprehensive portfolio of services and solutions, from development up to large-scale production.... Drug Research > Drug Discovery & Development > White Papers Contract Manufacturing By LABORATORIOS INIBSA
LABORATORIOS INIBSA is a pharmaceutical company with over 60 years of experience. We belong to the Group Inibsa. We provide products and services to group companies, such as Biotools, Keramat, Inibsa Portugal, Dental and Hospital, as well as other pharmaceutical companies through our contract manufacturing division.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 4834 results